News > Hyd: Covaxin Phase III trials kick start with NIMS

Hyd: Covaxin Phase III trials kick start with NIMS

The first and largest efficacy study for a Covid-19 vaccine in India kicked off on Monday with volunteers at the NIMS, Hyderabad, receiving the first dose of vaccine for Phase III trials of indigenous vaccine candidate Covaxin.

The Phase III trials for Covaxin, which is being developed by Bharat Biotech along with the Indian Council of Medical Research-National Institute of Virology, will involve 25,000 volunteers over 18 years of age across 25 centres in around 19 cities of the country.